Skip to main content
JIN YANG PHARMACEUTICAL. CO., LTD logo

JIN YANG PHARMACEUTICAL. CO., LTD — Investor Relations & Filings

Ticker · 007370 ISIN · KR7007370000 KO Manufacturing
Open in API
Filings indexed 210 across all filing types
Latest filing 2022-12-16 Notice of Dividend Amou…
Country KR South Korea
Listing KO 007370

About JIN YANG PHARMACEUTICAL. CO., LTD

https://www.jinyangpharm.com/

JIN YANG PHARMACEUTICAL. CO., LTD. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products, with a primary focus on prescription drugs. The company operates a fully automated, high-tech manufacturing facility. Its research and development efforts are dedicated to creating advanced preventive and therapeutic treatments for various diseases. Key areas of R&D include the development of anticancer drugs through molecular biology research, particularly for leukemia, and therapies for metabolic disorders such as diabetes and obesity. The company also develops antivirals and explores formulations based on herbal preparations.

Recent filings

Filing Released Lang Actions
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory announcement from Jinyang Pharmaceutical regarding the closure of the shareholder register to determine eligibility for dividends and the upcoming Annual General Meeting. It specifically mentions the setting of a record date for dividends and shareholder rights. Since it is an announcement of a corporate action (dividend record date) rather than the actual payment notice or the full report, it falls under the category of regulatory announcements regarding corporate actions.
2022-12-16 Korean
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the extension of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 연장결정). This falls under the category of company share buyback or repurchase activities. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct classification for reports of a company buying back or selling its own shares.
2022-11-18 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Jinyang Pharmaceutical Co., Ltd. covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial data, business operations, production capacity, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-10 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Jinyang Pharmaceutical. It provides a summary table of key financial metrics (revenue, operating profit, net income) for the third quarter of 2022 compared to previous periods. It is a short, high-level announcement of financial results rather than a full quarterly report or an audit report. According to the filing definitions, this fits the 'Earnings Release' (ER) category. Q3 2022
2022-10-27 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed with the Financial Supervisory Service (FSS) in South Korea. It details the specific dates, quantities, and prices of shares repurchased by Jinyang Pharm Co., Ltd. within a specified period. This falls directly under the category of 'Transaction in Own Shares' (POS), which covers share buybacks.
2022-09-21 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (CB) for Jinyang Pharmaceutical. It details the change in conversion price, the number of convertible shares, and the calculation methodology based on market price fluctuations. This falls under capital structure changes and financing updates, specifically related to convertible debt instruments.
2022-08-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.